PATIENTS AND METHODS : Younger ( < 60 years ; n = 175 ) and older ( > = 60 years ; n = 225 ) patients with CN-AML treated with intensive cytarabine / anthracycline -based first-line therapy on Cancer and Leukemia Group B protocols were centrally analyzed for RUNX1 mutations by polymerase chain reaction and direct sequencing and for established prognostic gene mutations .